Vaccine therapies for cancer: challenges and strategies
DOI:
https://doi.org/10.54097/0tfnsd31Keywords:
Cancer; vaccine; therapy; challenge.Abstract
Vaccine refers to the biological products that can make the body immune to specific diseases after inoculation and refers to biological products made with various pathogenic microorganisms for preventive vaccination. Vaccine is an effective means of disease prevention, especially for the control of epidemic diseases and infectious diseases play a vital role. Vaccines are mainly used to attenuate and inactivate pathogenic microorganisms, which can reduce their harm while retaining the ability of pathogens to stimulate organisms to produce immune responses. By injecting the vaccine, the organism can produce a specific immune response to the pathogenic microorganism, and the corresponding immune response can be quickly generated when it is exposed to the pathogenic microorganism again. Vaccination is a simple, safe and effective way to train a person's immune system to produce antibodies that can protect people from harmful diseases before they are even exposed to them. Vaccination uses the body's natural defense mechanisms to build resistance to specific infections and boost a person's immune system. In addition to preventing disease, vaccines are increasingly being used to treat cancer. Cancer vaccines, as part of cancer immunotherapy, can recognize specific proteins on cancer cells, stimulate the immune system, kill existing cancer cells and prevent cancer from continuing to develop. This review summarizes the types, clinical applications and development of cancer vaccines, and discusses the advantages and disadvantages of cancer vaccines as well as the opportunities and challenges for their future development.
Downloads
References
Zheng, R. S., Chen, R., Han, B. F., Wang, S. M., Li, L., Sun, K. X., Zeng, H. M., Wei, W. W., & He, J. (2024). Zhonghua zhong liu za zhi [Chinese journal of oncology], 46(3), 221–231. https://doi.org/10.3760/cma.j.cn112152-20240119-00035
Morse, M. A., Gwin, W. R., & Mitchell, D. A. (2021). Vaccine Therapies for Cancer: Then and Now. Targeted Oncology, 16(2), 121–152.https://doi.org/10.1007/s11523-020-00788-w
Hollingsworth, R. E., & Jansen, K. (2019). Turning the corner on therapeutic cancer vaccines. NPJ Vaccines, 4, 7. https://doi.org/10.1038/s41541-019-0103-y
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990). Direct gene transfer into mouse muscle in vivo. Science (New York, N.Y.), 247(4949 Pt 1), 1465–1468. https://doi.org/10.1126/science.1690918
Yang, B., Jeang, J., Yang, A., Wu, T. C., & Hung, C.-F. (2015). DNA vaccine for cancer immunotherapy. Human Vaccines & Immunotherapeutics, 10(11), 3153–3164. https://doi.org/10.4161/21645515.2014.980686
Porter, K. R., & Raviprakash, K. (2017). DNA Vaccine Delivery and Improved Immunogenicity. Current Issues in Molecular Biology, 129–138. https://doi.org/10.21775/cimb.022.129
[7] Ledesma-Feliciano, C., Chapman, R., Hooper, J. W., Elma, K., Zehrung, D., Brennan, M. B., & Spiegel, E. K. (2023). Improved DNA Vaccine Delivery with Needle-Free Injection Systems. Vaccines, 11(2), 280. https://doi.org/10.3390/vaccines11020280
Gote, V., Bolla, P. K., Kommineni, N., Butreddy, A., Nukala, P. K., Palakurthi, S. S., & Khan, W. (2023). A Comprehensive Review of mRNA Vaccines. International Journal of Molecular Sciences, 24(3), 2700. https://doi.org/10.3390/ijms24032700
Xu, S., Yang, K., Li, R., & Zhang, L. (2020). mRNA Vaccine Era—Mechanisms, Drug Platform and Clinical Prospection. International Journal of Molecular Sciences, 21(18), 6582. https://doi.org/10.3390/ijms21186582
Liu, X., Zhang, Y., Zhou, S., Dain, L., Mei, L., & Zhu, G. (2022). Circular RNA: An emerging frontier in RNA therapeutic targets, RNA therapeutics, and mRNA vaccines. Journal of Controlled Release: Official Journal of the Controlled Release Society, 348, 84–94. https://doi.org/10.1016/j.jconrel.2022.05.043
Santer, L., Bär, C., & Thum, T. (2019). Circular RNAs: A Novel Class of Functional RNA Molecules with a Therapeutic Perspective. Molecular Therapy, 27(8), 1350–1363. https://doi.org/10.1016/j.ymthe.2019.07.001
Niu, D., Wu, Y., & Lian, J. (2023). Circular RNA vaccine in disease prevention and treatment. Signal Transduction and Targeted Therapy, 8, 341. https://doi.org/10.1038/s41392-023-01561-x
Liu, W., Tang, H., Li, L., Wang, X., Yu, Z., & Li, J. (2021). Peptide‐based therapeutic cancer vaccine: Current trends in clinical application. Cell Proliferation, 54(5), e13025. https://doi.org/10.1111/cpr.13025
Buonaguro, L., & Tagliamonte, M. (2023). Peptide-based vaccine for cancer therapies. Frontiers in Immunology, 14, 1210044. https://doi.org/10.3389/fimmu.2023.1210044
Xie C Y, Yao R H & Xia X J. (2023). Advances in cancer vaccine research. Chinese Journal of Cell Biology (12),1931-1944.
Huang, X., Zhang, G., Tang, T. Y., GAO, X., & Liang, T. B. (2022). Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine. Military Medical Research, 9(1), 53. https://doi.org/10.1186/s40779-022-00416-w
1Vishweshwaraiah, Y. L., & Dokholyan, N. V. (2022). mRNA vaccines for cancer immunotherapy. Frontiers in immunology, 13, 1029069. https://doi.org/10.3389/fimmu.2022.1029069
Khan K. H. (2013). DNA vaccines: roles against diseases. Germs, 3(1), 26–35. https://doi.org/10.11599/germs.2013.1034
Yang Xiaoyi, Chen Juan, YAN Shu, LU Yan, OuYANG Zhao-lian. Analysis on global research and development of recombinant protein vaccines [J]. China Pharmaceutical Industry,2022,31(19):8-11.
Zhang T K. (2023). mRNA pathway for cancer vaccines. Encyclopedic Knowledge (01),47-50.
Liu C W, Long H H, Bao Y & Li W. (2023).mRNA vaccine technology and industry development overview. Chinese Food and Drug Regulation (12),74-84.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
